| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 390 @ USD 452.13 | USD 176,331 | The ETF bought 390 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 452.13 compared to the previous average buy price of 443.479. This is 2.0% higher than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 1,344 @ USD 121.6 | USD 163,430 | The ETF bought 1344 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 121.6 compared to the previous average buy price of 117.667. This is 3.3% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 490 @ USD 327.64 | USD 160,544 | The ETF bought 490 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 327.64 compared to the previous average buy price of 304.007. This is 7.8% higher than average price of previous purchases of AMGN. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 161 @ USD 776.31 | USD 124,986 | The ETF bought 161 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 776.31 compared to the previous average buy price of 651.929. This is 19.1% higher than average price of previous purchases of REGN. |
| AZN - AstraZeneca PLC | BUY | 908 @ USD 91.57 | USD 83,146 | The ETF bought 908 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 91.57 compared to the previous average buy price of 79.8765. This is 14.6% higher than average price of previous purchases of AZN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 206 @ USD 400.17 | USD 82,435 | The ETF bought 206 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 400.17 compared to the previous average buy price of 387.914. This is 3.2% higher than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 332 @ USD 177.12 | USD 58,804 | The ETF bought 332 new shares of INSM (Insmed Inc). The shares were bought for an average price of 177.12 compared to the previous average buy price of 142.9. This is 23.9% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 228 @ USD 177.82 | USD 40,543 | The ETF bought 228 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 177.82 compared to the previous average buy price of 149.905. This is 18.6% higher than average price of previous purchases of BIIB. |
| ARGX - argenx NV ADR | BUY | 45 @ USD 839.99 | USD 37,800 | The ETF bought 45 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 839.99 compared to the previous average buy price of 720.371. This is 16.6% higher than average price of previous purchases of ARGX. |
| UTHR - United Therapeutics Corporation | BUY | 67 @ USD 496.72 | USD 33,280 | The ETF bought 67 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 496.72 compared to the previous average buy price of 383.707. This is 29.5% higher than average price of previous purchases of UTHR. |
| ILMN - Illumina Inc | BUY | 238 @ USD 134.35 | USD 31,975 | The ETF bought 238 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 134.35 compared to the previous average buy price of 105.966. This is 26.8% higher than average price of previous purchases of ILMN. |
| INCY - Incyte Corporation | BUY | 305 @ USD 101.42 | USD 30,933 | The ETF bought 305 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 101.42 compared to the previous average buy price of 81.7949. This is 24.0% higher than average price of previous purchases of INCY. |
| RPRX - Royalty Pharma Plc | BUY | 665 @ USD 38.86 | USD 25,842 | The ETF bought 665 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 38.86 compared to the previous average buy price of 36.7215. This is 5.8% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 44 @ USD 571.02 | USD 25,125 | The ETF bought 44 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 571.02 compared to the previous average buy price of 446.695. This is 27.8% higher than average price of previous purchases of MEDP. |
| RVMD - Revolution Medicines Inc | BUY | 301 @ USD 79.02 | USD 23,785 | The ETF bought 301 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 79.02 compared to the previous average buy price of 50.5581. This is 56.3% higher than average price of previous purchases of RVMD. |
| ROIV - Roivant Sciences Ltd | BUY | 1,082 @ USD 21.93 | USD 23,728 | The ETF bought 1082 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 21.93 compared to the previous average buy price of 15.3538. This is 42.8% higher than average price of previous purchases of ROIV. |
| BBIO - BridgeBio Pharma Inc | BUY | 300 @ USD 78.235 | USD 23,471 | The ETF bought 300 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 78.235 compared to the previous average buy price of 52.4531. This is 49.2% higher than average price of previous purchases of BBIO. |
| VTRS - Viatris Inc | BUY | 1,792 @ USD 12.46 | USD 22,328 | The ETF bought 1792 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 12.46 compared to the previous average buy price of 9.95011. This is 25.2% higher than average price of previous purchases of VTRS. |
| NBIX - Neurocrine Biosciences Inc | BUY | 155 @ USD 140.6 | USD 21,793 | The ETF bought 155 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 140.6 compared to the previous average buy price of 135.79. This is 3.5% higher than average price of previous purchases of NBIX. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 35 @ USD 593.87 | USD 20,785 | The ETF bought 35 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 593.87 compared to the previous average buy price of 414.745. This is 43.2% higher than average price of previous purchases of MDGL. |
| ASND - Ascendis Pharma AS | BUY | 96 @ USD 213.29 | USD 20,476 | The ETF bought 96 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 213.29 compared to the previous average buy price of 186.84. This is 14.2% higher than average price of previous purchases of ASND. |
| GH - Guardant Health Inc | BUY | 201 @ USD 101.74 | USD 20,450 | The ETF bought 201 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 101.74 compared to the previous average buy price of 69.2173. This is 47.0% higher than average price of previous purchases of GH. |
| SMMT - Summit Therapeutics PLC | BUY | 1,158 @ USD 17.52 | USD 20,288 | The ETF bought 1158 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.52 compared to the previous average buy price of 20.2954. This is -13.7% lower than average price of previous purchases of SMMT. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 252 @ USD 79.67 | USD 20,077 | The ETF bought 252 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 79.67 compared to the previous average buy price of 57.2678. This is 39.1% higher than average price of previous purchases of IONS. |
| SNY - Sanofi ADR | BUY | 412 @ USD 48.23 | USD 19,871 | The ETF bought 412 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 48.23 compared to the previous average buy price of 49.8797. This is -3.3% lower than average price of previous purchases of SNY. |
| MRNA - Moderna Inc | BUY | 608 @ USD 30.86 | USD 18,763 | The ETF bought 608 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 30.86 compared to the previous average buy price of 28.0191. This is 10.1% higher than average price of previous purchases of MRNA. |
| EXEL - Exelixis Inc | BUY | 417 @ USD 43.58 | USD 18,173 | The ETF bought 417 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 43.58 compared to the previous average buy price of 41.7287. This is 4.4% higher than average price of previous purchases of EXEL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 299 @ USD 59.45 | USD 17,776 | The ETF bought 299 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 59.45 compared to the previous average buy price of 57.0333. This is 4.2% higher than average price of previous purchases of BMRN. |
| RNA - Avidity Biosciences Inc | BUY | 234 @ USD 72.1 | USD 16,871 | The ETF bought 234 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.1 compared to the previous average buy price of 51.0834. This is 41.1% higher than average price of previous purchases of RNA. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 95 @ USD 173.15 | USD 16,449 | The ETF bought 95 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 173.15 compared to the previous average buy price of 136.041. This is 27.3% higher than average price of previous purchases of JAZZ. |
| BNTX - BioNTech SE | BUY | 157 @ USD 96.69 | USD 15,180 | The ETF bought 157 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 96.69 compared to the previous average buy price of 102.84. This is -6.0% lower than average price of previous purchases of BNTX. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 211 @ USD 67.79 | USD 14,304 | The ETF bought 211 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 67.79 compared to the previous average buy price of 30.69. This is 120.9% higher than average price of previous purchases of ARWR. |
| AXSM - Axsome Therapeutics Inc | BUY | 78 @ USD 178.69 | USD 13,938 | The ETF bought 78 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 178.69 compared to the previous average buy price of 124.136. This is 43.9% higher than average price of previous purchases of AXSM. |
| HALO - Halozyme Therapeutics Inc | BUY | 183 @ USD 70.31 | USD 12,867 | The ETF bought 183 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 70.31 compared to the previous average buy price of 61.7166. This is 13.9% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 190 @ USD 61.73 | USD 11,729 | The ETF bought 190 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 61.73 compared to the previous average buy price of 49.3197. This is 25.2% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 112 @ USD 100.84 | USD 11,294 | The ETF bought 112 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 100.84 compared to the previous average buy price of 89.0116. This is 13.3% higher than average price of previous purchases of NUVL. |
| PRAX - Praxis Precision Medicines Inc | BUY | 39 @ USD 286.4 | USD 11,170 | The ETF bought 39 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 286.4 compared to the previous average buy price of 126.487. This is 126.4% higher than average price of previous purchases of PRAX. |
| KRYS - Krystal Biotech Inc | BUY | 45 @ USD 246.91 | USD 11,111 | The ETF bought 45 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 246.91 compared to the previous average buy price of 178.483. This is 38.3% higher than average price of previous purchases of KRYS. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 104 @ USD 105.01 | USD 10,921 | The ETF bought 104 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 105.01 compared to the previous average buy price of 84.0485. This is 24.9% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 125 @ USD 76.74 | USD 9,593 | The ETF bought 125 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 76.74 compared to the previous average buy price of 61.5667. This is 24.6% higher than average price of previous purchases of PTCT. |
| PCVX - Vaxcyte Inc | BUY | 204 @ USD 46.46 | USD 9,478 | The ETF bought 204 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 46.46 compared to the previous average buy price of 45.2664. This is 2.6% higher than average price of previous purchases of PCVX. |
| PTGX - Protagonist Therapeutics Inc | BUY | 97 @ USD 87.18 | USD 8,456 | The ETF bought 97 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 87.18 compared to the previous average buy price of 65.2743. This is 33.6% higher than average price of previous purchases of PTGX. |
| COGT - Cogent Biosciences Inc | BUY | 239 @ USD 34.74 | USD 8,303 | The ETF bought 239 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 34.74 compared to the previous average buy price of 20.1584. This is 72.3% higher than average price of previous purchases of COGT. |
| KYMR - Kymera Therapeutics Inc | BUY | 112 @ USD 72.76 | USD 8,149 | The ETF bought 112 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 72.76 compared to the previous average buy price of 52.8925. This is 37.6% higher than average price of previous purchases of KYMR. |
| CRSP - Crispr Therapeutics AG | BUY | 148 @ USD 53.77 | USD 7,958 | The ETF bought 148 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 53.77 compared to the previous average buy price of 53.2023. This is 1.1% higher than average price of previous purchases of CRSP. |
| ALKS - Alkermes Plc | BUY | 257 @ USD 28.26 | USD 7,263 | The ETF bought 257 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 28.26 compared to the previous average buy price of 30.0518. This is -6.0% lower than average price of previous purchases of ALKS. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 104 @ USD 68.12 | USD 7,084 | The ETF bought 104 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 68.12 compared to the previous average buy price of 31.2051. This is 118.3% higher than average price of previous purchases of GPCR. |
| IMVT - Immunovant Inc | BUY | 273 @ USD 25.91 | USD 7,073 | The ETF bought 273 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 25.91 compared to the previous average buy price of 19.2544. This is 34.6% higher than average price of previous purchases of IMVT. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 148 @ USD 46.73 | USD 6,916 | The ETF bought 148 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 46.73 compared to the previous average buy price of 38.1871. This is 22.4% higher than average price of previous purchases of CRNX. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 263 @ USD 26.29 | USD 6,914 | The ETF bought 263 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.29 compared to the previous average buy price of 22.1274. This is 18.8% higher than average price of previous purchases of ACAD. |
| FOLD - Amicus Therapeutics Inc | BUY | 481 @ USD 14.27 | USD 6,864 | The ETF bought 481 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.27 compared to the previous average buy price of 8.15776. This is 74.9% higher than average price of previous purchases of FOLD. |
| SRRK - Scholar Rock Holding Corp | BUY | 160 @ USD 42.8 | USD 6,848 | The ETF bought 160 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 42.8 compared to the previous average buy price of 36.9384. This is 15.9% higher than average price of previous purchases of SRRK. |
| ADMA - ADMA Biologics Inc | BUY | 371 @ USD 17.88 | USD 6,633 | The ETF bought 371 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 17.88 compared to the previous average buy price of 17.8155. This is 0.4% higher than average price of previous purchases of ADMA. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 85 @ USD 75.78 | USD 6,441 | The ETF bought 85 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 75.78 compared to the previous average buy price of 56.79. This is 33.4% higher than average price of previous purchases of APGE. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 80 @ USD 78.07 | USD 6,246 | The ETF bought 80 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 78.07 compared to the previous average buy price of 59.6505. This is 30.9% higher than average price of previous purchases of MIRM. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 490 @ USD 12.66 | USD 6,203 | The ETF bought 490 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.66 compared to the previous average buy price of 9.6919. This is 30.6% higher than average price of previous purchases of AMRX. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 31 @ USD 190.11 | USD 5,893 | The ETF bought 31 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 190.11 compared to the previous average buy price of 149.927. This is 26.8% higher than average price of previous purchases of LGND. |
| ACLX - Arcellx Inc | BUY | 90 @ USD 63.34 | USD 5,701 | The ETF bought 90 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 63.34 compared to the previous average buy price of 72.1979. This is -12.3% lower than average price of previous purchases of ACLX. |
| TERN - Tern Plc | BUY | 140 @ USD 40.11 | USD 5,615 | The ETF bought 140 new shares of TERN (Tern Plc). The shares were bought for an average price of 40.11 compared to the previous average buy price of 11.8898. This is 237.3% higher than average price of previous purchases of TERN. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 191 @ USD 29 | USD 5,539 | The ETF bought 191 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 29 compared to the previous average buy price of 20.34. This is 42.6% higher than average price of previous purchases of ARQT. |
| TVTX - Travere Therapeutics Inc | BUY | 139 @ USD 39.52 | USD 5,493 | The ETF bought 139 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 39.52 compared to the previous average buy price of 24.44. This is 61.7% higher than average price of previous purchases of TVTX. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 120 @ USD 44.49 | USD 5,339 | The ETF bought 120 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 44.49 compared to the previous average buy price of 37.7677. This is 17.8% higher than average price of previous purchases of XENE. |
| GRAL - GRAIL, LLC | BUY | 60 @ USD 88.87 | USD 5,332 | The ETF bought 60 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 88.87 compared to the previous average buy price of 64.7302. This is 37.3% higher than average price of previous purchases of GRAL. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 66 @ USD 80.77 | USD 5,331 | The ETF bought 66 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 80.77 compared to the previous average buy price of 57.1665. This is 41.3% higher than average price of previous purchases of TARS. |
| CGON - CG Oncology, Inc. Common stock | BUY | 125 @ USD 41.79 | USD 5,224 | The ETF bought 125 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 41.79 compared to the previous average buy price of 33.2223. This is 25.8% higher than average price of previous purchases of CGON. |
| VCYT - Veracyte Inc | BUY | 123 @ USD 42.39 | USD 5,214 | The ETF bought 123 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 42.39 compared to the previous average buy price of 35.1853. This is 20.5% higher than average price of previous purchases of VCYT. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 197 @ USD 25.86 | USD 5,094 | The ETF bought 197 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 25.86 compared to the previous average buy price of 21.1917. This is 22.0% higher than average price of previous purchases of APLS. |
| VERA - Vera Therapeutics Inc | BUY | 99 @ USD 48.62 | USD 4,813 | The ETF bought 99 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 48.62 compared to the previous average buy price of 30.5327. This is 59.2% higher than average price of previous purchases of VERA. |
| IDYA - Ideaya Biosciences Inc | BUY | 136 @ USD 33.85 | USD 4,604 | The ETF bought 136 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 33.85 compared to the previous average buy price of 26.3255. This is 28.6% higher than average price of previous purchases of IDYA. |
| IRON - Ironveld Plc | BUY | 58 @ USD 79.09 | USD 4,587 | The ETF bought 58 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 79.09 compared to the previous average buy price of 66.4264. This is 19.1% higher than average price of previous purchases of IRON. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 89 @ USD 49.47 | USD 4,403 | The ETF bought 89 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 49.47 compared to the previous average buy price of 39.6785. This is 24.7% higher than average price of previous purchases of SUPN. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 123 @ USD 35.71 | USD 4,392 | The ETF bought 123 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 35.71 compared to the previous average buy price of 26.4128. This is 35.2% higher than average price of previous purchases of MLYS. |
| BEAM - Beam Therapeutics Inc | BUY | 158 @ USD 27.14 | USD 4,288 | The ETF bought 158 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 27.14 compared to the previous average buy price of 21.9953. This is 23.4% higher than average price of previous purchases of BEAM. |
| WVE - Wave Life Sciences Ltd | BUY | 260 @ USD 15.95 | USD 4,147 | The ETF bought 260 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 15.95 compared to the previous average buy price of 8.36515. This is 90.7% higher than average price of previous purchases of WVE. |
| DYN - Dyne Therapeutics Inc | BUY | 222 @ USD 18.5 | USD 4,107 | The ETF bought 222 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 18.5 compared to the previous average buy price of 14.9192. This is 24.0% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 222 @ USD 18.5 | USD 4,107 | The ETF bought 222 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 18.5 compared to the previous average buy price of 14.9192. This is 24.0% higher than average price of previous purchases of DYN. |
| OCUL - Ocular Therapeutix Inc | BUY | 332 @ USD 11.82 | USD 3,924 | The ETF bought 332 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 11.82 compared to the previous average buy price of 11.0101. This is 7.4% higher than average price of previous purchases of OCUL. |
| EWTX - Edgewise Therapeutics Inc | BUY | 165 @ USD 23.75 | USD 3,919 | The ETF bought 165 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 23.75 compared to the previous average buy price of 18.0693. This is 31.4% higher than average price of previous purchases of EWTX. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 238 @ USD 15.91 | USD 3,787 | The ETF bought 238 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 15.91 compared to the previous average buy price of 13.5176. This is 17.7% higher than average price of previous purchases of ADPT. |
| DNLI - Denali Therapeutics Inc | BUY | 229 @ USD 16.27 | USD 3,726 | The ETF bought 229 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 16.27 compared to the previous average buy price of 16.2146. This is 0.3% higher than average price of previous purchases of DNLI. |
| SYRE - Spyre Therapeutics Inc. | BUY | 121 @ USD 30.58 | USD 3,700 | The ETF bought 121 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 30.58 compared to the previous average buy price of 24.7055. This is 23.8% higher than average price of previous purchases of SYRE. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 150 @ USD 23.69 | USD 3,554 | The ETF bought 150 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 23.69 compared to the previous average buy price of 19.625. This is 20.7% higher than average price of previous purchases of CNTA. |
| RARE - Ultragenyx | BUY | 150 @ USD 23.6 | USD 3,540 | The ETF bought 150 new shares of RARE (Ultragenyx). The shares were bought for an average price of 23.6 compared to the previous average buy price of 35.928. This is -34.3% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 150 @ USD 23.6 | USD 3,540 | The ETF bought 150 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 23.6 compared to the previous average buy price of 35.928. This is -34.3% lower than average price of previous purchases of RARE. |
| SRPT - Sarepta Therapeutics Inc | BUY | 166 @ USD 21.31 | USD 3,537 | The ETF bought 166 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 21.31 compared to the previous average buy price of 30.2338. This is -29.5% lower than average price of previous purchases of SRPT. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 803 @ USD 4.2 | USD 3,373 | The ETF bought 803 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.2 compared to the previous average buy price of 5.2931. This is -20.7% lower than average price of previous purchases of RXRX. |
| HRMY - Harmony Biosciences Holdings | BUY | 90 @ USD 37.38 | USD 3,364 | The ETF bought 90 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 37.38 compared to the previous average buy price of 33.4267. This is 11.8% higher than average price of previous purchases of HRMY. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 206 @ USD 15.35 | USD 3,162 | The ETF bought 206 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 15.35 compared to the previous average buy price of 11.4376. This is 34.2% higher than average price of previous purchases of AUPH. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 117 @ USD 26.62 | USD 3,115 | The ETF bought 117 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 26.62 compared to the previous average buy price of 17.4985. This is 52.1% higher than average price of previous purchases of ZYME. |
| IBRX - Immunitybio Inc | BUY | 1,539 @ USD 2.02 | USD 3,109 | The ETF bought 1539 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.02 compared to the previous average buy price of 2.62854. This is -23.2% lower than average price of previous purchases of IBRX. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 122 @ USD 25.28 | USD 3,084 | The ETF bought 122 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 25.28 compared to the previous average buy price of 12.8371. This is 96.9% higher than average price of previous purchases of OLMA. |
| TWST - Twist Bioscience Corp | BUY | 95 @ USD 32.39 | USD 3,077 | The ETF bought 95 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 32.39 compared to the previous average buy price of 34.5809. This is -6.3% lower than average price of previous purchases of TWST. |
| TXG - 10X Genomics Inc | BUY | 182 @ USD 16.62 | USD 3,025 | The ETF bought 182 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 16.62 compared to the previous average buy price of 13.6133. This is 22.1% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 182 @ USD 16.62 | USD 3,025 | The ETF bought 182 new shares of TXG (Terex Corporation). The shares were bought for an average price of 16.62 compared to the previous average buy price of 13.6133. This is 22.1% higher than average price of previous purchases of TXG. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 70 @ USD 42.005 | USD 2,940 | The ETF bought 70 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 42.005 compared to the previous average buy price of 32.9528. This is 27.5% higher than average price of previous purchases of KNSA. |
| GMAB - Genmab AS | BUY | 91 @ USD 31.82 | USD 2,896 | The ETF bought 91 new shares of GMAB (Genmab AS). The shares were bought for an average price of 31.82 compared to the previous average buy price of 28.2651. This is 12.6% higher than average price of previous purchases of GMAB. |
| HROW - Harrow Health Inc | BUY | 58 @ USD 49.91 | USD 2,895 | The ETF bought 58 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 49.91 compared to the previous average buy price of 37.2752. This is 33.9% higher than average price of previous purchases of HROW. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 135 @ USD 21.3 | USD 2,876 | The ETF bought 135 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 21.3 compared to the previous average buy price of 14.187. This is 50.1% higher than average price of previous purchases of SNDX. |
| NRIX - Nurix Therapeutics Inc | BUY | 158 @ USD 18.06 | USD 2,853 | The ETF bought 158 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 18.06 compared to the previous average buy price of 14.6857. This is 23.0% higher than average price of previous purchases of NRIX. |
| LEGN - Legend Biotech Corp | BUY | 131 @ USD 21.51 | USD 2,818 | The ETF bought 131 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 21.51 compared to the previous average buy price of 32.4995. This is -33.8% lower than average price of previous purchases of LEGN. |
| DVAX - Dynavax Technologies Corporation | BUY | 183 @ USD 15.38 | USD 2,815 | The ETF bought 183 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.38 compared to the previous average buy price of 10.653. This is 44.4% higher than average price of previous purchases of DVAX. |
| VCEL - Vericel Corp Ord | BUY | 79 @ USD 35.61 | USD 2,813 | The ETF bought 79 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 35.61 compared to the previous average buy price of 39.8664. This is -10.7% lower than average price of previous purchases of VCEL. |
| STOK - Stoke Therapeutics Inc | BUY | 89 @ USD 30.9 | USD 2,750 | The ETF bought 89 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 30.9 compared to the previous average buy price of 19.899. This is 55.3% higher than average price of previous purchases of STOK. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 35 @ USD 78.43 | USD 2,745 | The ETF bought 35 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 78.43 compared to the previous average buy price of 75.8174. This is 3.4% higher than average price of previous purchases of ANIP. |
| MNKD - MannKind Corp | BUY | 480 @ USD 5.6 | USD 2,688 | The ETF bought 480 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.6 compared to the previous average buy price of 4.98219. This is 12.4% higher than average price of previous purchases of MNKD. |
| PHVS - Pharvaris BV | BUY | 100 @ USD 26.48 | USD 2,648 | The ETF bought 100 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 26.48 compared to the previous average buy price of 26.2236. This is 1.0% higher than average price of previous purchases of PHVS. |
| AGIO - Agios Pharm | BUY | 91 @ USD 27.18 | USD 2,473 | The ETF bought 91 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 27.18 compared to the previous average buy price of 33.8108. This is -19.6% lower than average price of previous purchases of AGIO. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 329 @ USD 7.5 | USD 2,468 | The ETF bought 329 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.5 compared to the previous average buy price of 8.0318. This is -6.6% lower than average price of previous purchases of BCRX. |
| FTRE - Fortrea Holdings Inc. | BUY | 144 @ USD 16.81 | USD 2,421 | The ETF bought 144 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 16.81 compared to the previous average buy price of 8.55408. This is 96.5% higher than average price of previous purchases of FTRE. |
| PGEN - Precigen Inc | BUY | 554 @ USD 4.28 | USD 2,371 | The ETF bought 554 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.28 compared to the previous average buy price of 2.99636. This is 42.8% higher than average price of previous purchases of PGEN. |
| ARDX - Ardelyx Inc | BUY | 380 @ USD 6.15 | USD 2,337 | The ETF bought 380 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 6.15 compared to the previous average buy price of 4.93888. This is 24.5% higher than average price of previous purchases of ARDX. |
| INVA - Innoviva Inc | BUY | 117 @ USD 19.87 | USD 2,325 | The ETF bought 117 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 19.87 compared to the previous average buy price of 19.6901. This is 0.9% higher than average price of previous purchases of INVA. |
| IMCR - Immunocore Holdings Ltd | BUY | 68 @ USD 33.78 | USD 2,297 | The ETF bought 68 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 33.78 compared to the previous average buy price of 34.3296. This is -1.6% lower than average price of previous purchases of IMCR. |
| NVCR - Novocure Ltd | BUY | 175 @ USD 13.12 | USD 2,296 | The ETF bought 175 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 13.12 compared to the previous average buy price of 15.4323. This is -15.0% lower than average price of previous purchases of NVCR. |
| QURE - Uniqure NV | BUY | 97 @ USD 23.39 | USD 2,269 | The ETF bought 97 new shares of QURE (Uniqure NV). The shares were bought for an average price of 23.39 compared to the previous average buy price of 23.6731. This is -1.2% lower than average price of previous purchases of QURE. |
| TSHA - Taysha Gene Therapies Inc | BUY | 428 @ USD 5.25 | USD 2,247 | The ETF bought 428 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 5.25 compared to the previous average buy price of 3.28955. This is 59.6% higher than average price of previous purchases of TSHA. |
| COLL - Collegium Pharmaceutical Inc | BUY | 49 @ USD 45.53 | USD 2,231 | The ETF bought 49 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 45.53 compared to the previous average buy price of 35.8173. This is 27.1% higher than average price of previous purchases of COLL. |
| RLAY - Relay Therapeutics Inc | BUY | 271 @ USD 8.18 | USD 2,217 | The ETF bought 271 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.18 compared to the previous average buy price of 4.93906. This is 65.6% higher than average price of previous purchases of RLAY. |
| MNMD - Mind Medicine Inc | BUY | 154 @ USD 13.64 | USD 2,101 | The ETF bought 154 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 13.64 compared to the previous average buy price of 10.4844. This is 30.1% higher than average price of previous purchases of MNMD. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 172 @ USD 11.42 | USD 1,964 | The ETF bought 172 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 11.42 compared to the previous average buy price of 9.18379. This is 24.3% higher than average price of previous purchases of AMLX. |
| ANAB - AnaptysBio Inc | BUY | 43 @ USD 44.95 | USD 1,933 | The ETF bought 43 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 44.95 compared to the previous average buy price of 28.6696. This is 56.8% higher than average price of previous purchases of ANAB. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 260 @ USD 7.35 | USD 1,911 | The ETF bought 260 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.35 compared to the previous average buy price of 6.2552. This is 17.5% higher than average price of previous purchases of XERS. |
| AMPH - Amphastar P | BUY | 72 @ USD 26.46 | USD 1,905 | The ETF bought 72 new shares of AMPH (Amphastar P). The shares were bought for an average price of 26.46 compared to the previous average buy price of 25.9465. This is 2.0% higher than average price of previous purchases of AMPH. |
| TNGX - Tango Therapeutics Inc | BUY | 211 @ USD 8.93 | USD 1,884 | The ETF bought 211 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 8.93 compared to the previous average buy price of 7.62391. This is 17.1% higher than average price of previous purchases of TNGX. |
| NVAX - Novavax Inc | BUY | 254 @ USD 7.13 | USD 1,811 | The ETF bought 254 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 7.13 compared to the previous average buy price of 7.216. This is -1.2% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 254 @ USD 7.13 | USD 1,811 | The ETF bought 254 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 7.13 compared to the previous average buy price of 7.216. This is -1.2% lower than average price of previous purchases of NVAX. |
| SVRA - Savara Inc | BUY | 319 @ USD 5.64 | USD 1,799 | The ETF bought 319 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.64 compared to the previous average buy price of 4.25629. This is 32.5% higher than average price of previous purchases of SVRA. |
| SPRY - Silverback Therapeutics Inc | BUY | 155 @ USD 11.49 | USD 1,781 | The ETF bought 155 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 11.49 compared to the previous average buy price of 12.3038. This is -6.6% lower than average price of previous purchases of SPRY. |
| GRFS - Grifols SA ADR | BUY | 191 @ USD 9.24 | USD 1,765 | The ETF bought 191 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.24 compared to the previous average buy price of 9.17346. This is 0.7% higher than average price of previous purchases of GRFS. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 111 @ USD 15.71 | USD 1,744 | The ETF bought 111 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 15.71 compared to the previous average buy price of 10.6264. This is 47.8% higher than average price of previous purchases of PHAT. |
| SANA - Sana Biotechnology Inc | BUY | 416 @ USD 4.19 | USD 1,743 | The ETF bought 416 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 4.19 compared to the previous average buy price of 3.49038. This is 20.0% higher than average price of previous purchases of SANA. |
| CSTL - Castle Biosciences Inc | BUY | 45 @ USD 38.54 | USD 1,734 | The ETF bought 45 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 38.54 compared to the previous average buy price of 26.5263. This is 45.3% higher than average price of previous purchases of CSTL. |
| XNCR - Xencor Inc | BUY | 112 @ USD 14.92 | USD 1,671 | The ETF bought 112 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 14.92 compared to the previous average buy price of 12.6341. This is 18.1% higher than average price of previous purchases of XNCR. |
| NTLA - Intellia Therapeutics Inc | BUY | 181 @ USD 9.21 | USD 1,667 | The ETF bought 181 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 9.21 compared to the previous average buy price of 11.4386. This is -19.5% lower than average price of previous purchases of NTLA. |
| URGN - UroGen Pharma Ltd | BUY | 73 @ USD 22.71 | USD 1,658 | The ETF bought 73 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 22.71 compared to the previous average buy price of 17.0266. This is 33.4% higher than average price of previous purchases of URGN. |
| PCRX - Pacira BioSciences, Inc. | BUY | 67 @ USD 24.46 | USD 1,639 | The ETF bought 67 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 24.46 compared to the previous average buy price of 23.9238. This is 2.2% higher than average price of previous purchases of PCRX. |
| ABCL - Abcellera Biologics Inc | BUY | 467 @ USD 3.43 | USD 1,602 | The ETF bought 467 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.43 compared to the previous average buy price of 3.82493. This is -10.3% lower than average price of previous purchases of ABCL. |
| ERAS - Erasca Inc | BUY | 445 @ USD 3.59 | USD 1,598 | The ETF bought 445 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 3.59 compared to the previous average buy price of 2.04465. This is 75.6% higher than average price of previous purchases of ERAS. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 591 @ USD 2.52 | USD 1,489 | The ETF bought 591 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.52 compared to the previous average buy price of 2.39461. This is 5.2% higher than average price of previous purchases of IOVA. |
| ABUS - Arbutus Biopharma Corp | BUY | 302 @ USD 4.77 | USD 1,441 | The ETF bought 302 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.77 compared to the previous average buy price of 3.8593. This is 23.6% higher than average price of previous purchases of ABUS. |
| ELVN - Enliven Therapeutics Inc. | BUY | 92 @ USD 15.54 | USD 1,430 | The ETF bought 92 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 15.54 compared to the previous average buy price of 20.8911. This is -25.6% lower than average price of previous purchases of ELVN. |
| TBPH - Theravance Biopharma Inc | BUY | 78 @ USD 18.15 | USD 1,416 | The ETF bought 78 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 18.15 compared to the previous average buy price of 13.6284. This is 33.2% higher than average price of previous purchases of TBPH. |
| KURA - Kura Oncology Inc | BUY | 136 @ USD 10.335 | USD 1,406 | The ETF bought 136 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 10.335 compared to the previous average buy price of 8.33692. This is 24.0% higher than average price of previous purchases of KURA. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 157 @ USD 8.85 | USD 1,389 | The ETF bought 157 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.85 compared to the previous average buy price of 7.7437. This is 14.3% higher than average price of previous purchases of DAWN. |
| RAPT - RAPT Therapeutics Inc | BUY | 43 @ USD 31.85 | USD 1,370 | The ETF bought 43 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 31.85 compared to the previous average buy price of 33.38. This is -4.6% lower than average price of previous purchases of RAPT. |
| GERN - Geron Corporation | BUY | 982 @ USD 1.32 | USD 1,296 | The ETF bought 982 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.32 compared to the previous average buy price of 1.44505. This is -8.7% lower than average price of previous purchases of GERN. |
| VIR - Vir Biotechnology Inc | BUY | 213 @ USD 5.94 | USD 1,265 | The ETF bought 213 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.94 compared to the previous average buy price of 5.93628. This is 0.1% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 213 @ USD 5.94 | USD 1,265 | The ETF bought 213 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.94 compared to the previous average buy price of 5.93628. This is 0.1% higher than average price of previous purchases of VIR. |
| JANX - Janux Therapeutics Inc | BUY | 92 @ USD 13.65 | USD 1,256 | The ETF bought 92 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 13.65 compared to the previous average buy price of 26.2276. This is -48.0% lower than average price of previous purchases of JANX. |
| PAHC - Phibro Animal Health Corporation | BUY | 33 @ USD 37.3 | USD 1,231 | The ETF bought 33 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 37.3 compared to the previous average buy price of 31.558. This is 18.2% higher than average price of previous purchases of PAHC. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 79 @ USD 15.46 | USD 1,221 | The ETF bought 79 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 15.46 compared to the previous average buy price of 13.5466. This is 14.1% higher than average price of previous purchases of KALV. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 149 @ USD 8.17001 | USD 1,217 | The ETF bought 149 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 8.17001 compared to the previous average buy price of 10.6997. This is -23.6% lower than average price of previous purchases of ORIC. |
| ARVN - Arvinas Inc | BUY | 101 @ USD 11.47 | USD 1,158 | The ETF bought 101 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 11.47 compared to the previous average buy price of 9.98096. This is 14.9% higher than average price of previous purchases of ARVN. |
| REPL - Replimune Group Inc | BUY | 123 @ USD 8.89999 | USD 1,095 | The ETF bought 123 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 8.89999 compared to the previous average buy price of 9.21689. This is -3.4% lower than average price of previous purchases of REPL. |
| RGNX - Regenxbio Inc | BUY | 79 @ USD 13.57 | USD 1,072 | The ETF bought 79 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 13.57 compared to the previous average buy price of 10.0841. This is 34.6% higher than average price of previous purchases of RGNX. |
| ZLAB - Zai Lab Ltd | BUY | 61 @ USD 17.33 | USD 1,057 | The ETF bought 61 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 17.33 compared to the previous average buy price of 30.913. This is -43.9% lower than average price of previous purchases of ZLAB. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 293 @ USD 3.53 | USD 1,034 | The ETF bought 293 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.53 compared to the previous average buy price of 3.86963. This is -8.8% lower than average price of previous purchases of PRME. |
| MGTX - MeiraGTx Holdings PLC | BUY | 122 @ USD 7.80999 | USD 953 | The ETF bought 122 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.80999 compared to the previous average buy price of 7.42147. This is 5.2% higher than average price of previous purchases of MGTX. |
| VTYX - Ventyx Biosciences Inc | BUY | 112 @ USD 8.40001 | USD 941 | The ETF bought 112 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 8.40001 compared to the previous average buy price of 8.75. This is -4.0% lower than average price of previous purchases of VTYX. |
| FULC - Fulcrum Therapeutics Inc | BUY | 85 @ USD 10.92 | USD 928 | The ETF bought 85 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 10.92 compared to the previous average buy price of 11.34. This is -3.7% lower than average price of previous purchases of FULC. |
| LYEL - Lyell Immunopharma Inc | BUY | 32 @ USD 28.98 | USD 927 | The ETF bought 32 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 28.98 compared to the previous average buy price of 7.19397. This is 302.8% higher than average price of previous purchases of LYEL. |
| CGEM - Cullinan Oncology LLC | BUY | 91 @ USD 10.12 | USD 921 | The ETF bought 91 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 10.12 compared to the previous average buy price of 8.60108. This is 17.7% higher than average price of previous purchases of CGEM. |
| KROS - Keros Therapeutics Inc | BUY | 48 @ USD 18.54 | USD 890 | The ETF bought 48 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 18.54 compared to the previous average buy price of 15.893. This is 16.7% higher than average price of previous purchases of KROS. |
| PACB - Pacific Biosciences of California | BUY | 478 @ USD 1.84 | USD 880 | The ETF bought 478 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 1.84 compared to the previous average buy price of 1.72926. This is 6.4% higher than average price of previous purchases of PACB. |
| PRTA - Prothena Corporation plc | BUY | 92 @ USD 9.2 | USD 846 | The ETF bought 92 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 9.2 compared to the previous average buy price of 9.51879. This is -3.3% lower than average price of previous purchases of PRTA. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 230 @ USD 3.4 | USD 782 | The ETF bought 230 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.4 compared to the previous average buy price of 2.94649. This is 15.4% higher than average price of previous purchases of MRVI. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 92 @ USD 8.25001 | USD 759 | The ETF bought 92 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 8.25001 compared to the previous average buy price of 4.94229. This is 66.9% higher than average price of previous purchases of VNDA. |
| SIGA - SIGA Technologies Inc | BUY | 119 @ USD 6.26999 | USD 746 | The ETF bought 119 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.26999 compared to the previous average buy price of 6.62697. This is -5.4% lower than average price of previous purchases of SIGA. |
| GLPG - Galapagos NV ADR | BUY | 22 @ USD 32.97 | USD 725 | The ETF bought 22 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 32.97 compared to the previous average buy price of 29.6877. This is 11.1% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 22 @ USD 32.97 | USD 725 | The ETF bought 22 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 32.97 compared to the previous average buy price of 29.6877. This is 11.1% higher than average price of previous purchases of GLPG. |
| EOLS - Evolus Inc | BUY | 103 @ USD 6.71999 | USD 692 | The ETF bought 103 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.71999 compared to the previous average buy price of 8.55224. This is -21.4% lower than average price of previous purchases of EOLS. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 181 @ USD 3.46 | USD 626 | The ETF bought 181 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.46 compared to the previous average buy price of 4.67491. This is -26.0% lower than average price of previous purchases of RCKT. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 84 @ USD 7.31999 | USD 615 | The ETF bought 84 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 7.31999 compared to the previous average buy price of 7.85355. This is -6.8% lower than average price of previous purchases of FDMT. |
| TRDA - Entrada Therapeutics Inc | BUY | 60 @ USD 10.05 | USD 603 | The ETF bought 60 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.05 compared to the previous average buy price of 8.27666. This is 21.4% higher than average price of previous purchases of TRDA. |
| ALT - Altitude Group Plc | BUY | 166 @ USD 3.51 | USD 583 | The ETF bought 166 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 3.51 compared to the previous average buy price of 4.90978. This is -28.5% lower than average price of previous purchases of ALT. |
| ACIU - AC Immune Ltd | BUY | 170 @ USD 3.36 | USD 571 | The ETF bought 170 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.36 compared to the previous average buy price of 2.58405. This is 30.0% higher than average price of previous purchases of ACIU. |
| AUTL - Autolus Therapeutics Ltd | BUY | 302 @ USD 1.87 | USD 565 | The ETF bought 302 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.87 compared to the previous average buy price of 1.72762. This is 8.2% higher than average price of previous purchases of AUTL. |
| AVXL - Anavex Life Sciences Corp | BUY | 146 @ USD 3.68001 | USD 537 | The ETF bought 146 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 3.68001 compared to the previous average buy price of 7.98133. This is -53.9% lower than average price of previous purchases of AVXL. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 80 @ USD 6.68 | USD 534 | The ETF bought 80 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.68 compared to the previous average buy price of 8.1472. This is -18.0% lower than average price of previous purchases of BCYC. |
| ALLO - Allogene Therapeutics Inc | BUY | 374 @ USD 1.35 | USD 505 | The ETF bought 374 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.35 compared to the previous average buy price of 1.34942. This is 0.0% higher than average price of previous purchases of ALLO. |
| ACRS - Aclaris Therapeutics Inc | BUY | 173 @ USD 2.88 | USD 498 | The ETF bought 173 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 2.88 compared to the previous average buy price of 2.9. This is -0.7% lower than average price of previous purchases of ACRS. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 143 @ USD 3.47999 | USD 498 | The ETF bought 143 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.47999 compared to the previous average buy price of 3.24025. This is 7.4% higher than average price of previous purchases of AVIR. |
| OABI - OmniAb Inc. | BUY | 213 @ USD 1.88 | USD 400 | The ETF bought 213 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.88 compared to the previous average buy price of 1.88452. This is -0.2% lower than average price of previous purchases of OABI. |
| VYGR - Voyager Therapeutics Inc | BUY | 89 @ USD 4.03001 | USD 359 | The ETF bought 89 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.03001 compared to the previous average buy price of 3.94781. This is 2.1% higher than average price of previous purchases of VYGR. |
| CABA - Cabaletta Bio Inc | BUY | 157 @ USD 2.21001 | USD 347 | The ETF bought 157 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 2.21001 compared to the previous average buy price of 2.15. This is 2.8% higher than average price of previous purchases of CABA. |
| EDIT - Editas Medicine Inc | BUY | 166 @ USD 2.05001 | USD 340 | The ETF bought 166 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.05001 compared to the previous average buy price of 2.61072. This is -21.5% lower than average price of previous purchases of EDIT. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 49 @ USD 6.25001 | USD 306 | The ETF bought 49 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 6.25001 compared to the previous average buy price of 12.4743. This is -49.9% lower than average price of previous purchases of ARCT. |
| HUMA - Humacyte Inc | BUY | 282 @ USD 0.974996 | USD 275 | The ETF bought 282 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 0.974996 compared to the previous average buy price of 1.97683. This is -50.7% lower than average price of previous purchases of HUMA. |
| CRBU - Caribou Biosciences Inc | BUY | 152 @ USD 1.58999 | USD 242 | The ETF bought 152 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.58999 compared to the previous average buy price of 1.70669. This is -6.8% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 4.27 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 4.27. The average price that IRWD shares were previous bought at was USD 2.38611. The current market price is 79.0% higher than average price they were purchased at. The value of the holding in IRWD has increased by USD 97,594 compared to the previous valuation of Ironwood Pharmaceuticals Inc however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-02 this would crystalise an overall loss. |